Aluminium compounds for use in vaccines

Immunology and Cell Biology

Volumn 82, Issue 5, 2004, Pages 497-505

  Lindblad, Erik B ^a  

^a Brenntag Biosector   (Denmark)

Author keywords

Adjuvant; Aluminium; Cytokine; Mineral; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM DERIVATIVE; ALUMINUM HYDROXIDE; ALUMINUM HYDROXYPHOSPHATE; ALUMINUM OXIDE; ALUMINUM PHOSPHATE; ANTIGEN; BACTERIAL TOXIN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DNA VACCINE; FORMALDEHYDE; IMMUNOGLOBULIN E; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MINERAL; PRESERVATIVE; PROPIOLACTONE; THIOMERSAL; UNCLASSIFIED DRUG; VACCINE; WATER OIL CREAM;

ADSORPTION; ANALYTIC METHOD; CARCINOGENICITY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG MECHANISM; DRUG SAFETY; EDEMA; FEVER; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KNOCKOUT MOUSE; LEUKOPENIA; NONHUMAN; PRURITUS; REVIEW; SHIVERING; SIDE EFFECT; SKIN IRRITATION; T LYMPHOCYTE ACTIVATION; TERATOGENICITY; TH1 CELL; TH2 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; HUMANS; IMMUNOGLOBULIN E; T-LYMPHOCYTE SUBSETS; VACCINES;

BACTERIA (MICROORGANISMS);

EID: 7044274793     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0818-9641.2004.01286.x     Document Type: Review

References (88)

1. World Health Organization. Immunological Adjuvants. Technical Report Series 595. Geneva: World Health Organization, 1976.
2. Edelman R. Vaccine Adjuvants. Rev. Infect. Dis. 1980; 2: 370-83.
3. McDougall JS. Avian Infectious Bronchitis: The Protection Afforded by an Inactivated Virus Vaccine. Vet. Rec. 1969; 85: 378-80.
4. Wilson JHG, Hermann-Dekkers WM, Leemans-Dessy S, de Meijer JW. Experiments with an inactivated hepatitis leptospirosis vaccine in vaccination programmes for dogs. Vet. Rec. 1977; 100: 552-4.
5. Sellers RF, Herniman KAJ. Early Protection of Pigs Against Foot-and-Mouth Disease. Br. Vet. J. 1974; 130: 440-5.
6. Hyslop NStG, Morrow AW. The Influence of Aluminium Hydroxide Content, Dose Volume and the Inclusion of Saponin on the Efficacy of Inactivated Foot-and-Mouth Disease Vaccines. Res. Vet. Sci. 1969; 10: 109-20.
7. Pini A, Danskin D, Coackley W. Comparative Evaluation of the Potency of Beta-propiolactone Inactivated Newcastle Disease Vaccines Prepared from a Lentogenic and a Velogenic Strain. Vet. Rec. 1965; 77: 127-9.
8. Thorley CM, Egerton JR. Comparison of Alum-Adsorbed or Non-Alum-Adsorbed Oil Emulsion Vaccines Containing, either Pilate or Non-Pilate Bacteroides nodosus Cells in Inducing and Maintaining Resistance of Sheep to Experimental Foot Rot. Res. Vet. Sci. 1981; 30: 32-7.
9. McCandlish IAP, Thompson H, Wright NG. Vaccination Against Canine Bordetellosis using an Aluminium Hydroxide Adjuvant Vaccine. Res. Vet. Sci. 1978; 25: 51-7.
10. Nagy LK, Penn CW. Protective Antigens in Bovine Pasteurellosis. Dev. Biol. Stand. 1974; 26: 65-76.
11. Ris DR, Hamel KL. Leptospira interrogans serovar: pomona Vaccines with Different Adjuvants in Cattle. NZ Vet. J. 1979; 27: 169-71.
12. Leland SE, Sofield WL, Minocha HC. Immunogenic Effects of Culture-Derived Exoantigens of Cooperia punctata on Calves Before and After Challenge Exposure with Infective Larvae. Am. J. Vet. Res. 1988; 49: 366-79.
13. Monroy FG, Adams JH, Dobson C, Bast IJ. Nematospiroides dubius: Influence of Adjuvants on Immunity in Mice Vaccinated with Antigens Isolated by Affinity Chromatography from Adult Worms. Exp. Parasitol. 1989; 68: 67-73.
14. Carlow CKS, Bianco AE. Resistance of Onchocerca lienalis Microfilariae in Mice Conferred by Egg Antigens of Homologous and Heterologous Onchocerca Species. Parasitology 1987; 94: 485-96.
15. Gamble HR, Murrell KD, Marti HP. Inoculation of Pigs Against Trichinella spiralis using Larval Excretory-Secretory Antigens. Am. J. Vet. Res. 1986; 47: 2396-9.
16. Glenny AT, Pope CG, Waddington H, Wallace U. Immunological Notes XVII to XXIV. J. Pathol. 1926; 29: 31-40.
17. Glenny AT, Buttle GAH, Stevens MF. Rate of Disappearance of Diphtheria Toxoid Injected into Rabbits and Guinea-Pigs: Toxoid Precipitated with Alum. J. Pathol. 1931; 34: 267-75.
18. Holt LB. Developments in Diphtheria Prophylaxis. London: Heinemann Ltd, 1950.
19. Maschmann E, Küster E, Fischer W. Über die Fähigkeit des Tonerde-Präparates B, Diphtherie-Toxin zu adsorbieren. Ber. Dtsch. Chem. Ges. 1931; 64: 2174-8.
20. Ericsson H. Purification and adsorption of diphtheria toxoid. Nature 1946; 158: 350-1.
21. Holt LB. Purified precipitated diphtheria toxoid of constant composition. Lancet 1947; 8: 282-5.
22. Volk VK, Bunney WE. Diphtheria immunization with fluid toxoid and alum-precipitated toxoid. Am. J. Public Health 1942; 32: 690-9.
23. Kawamura Y, Sawai Y. Study on Indian Cobra Venom Toxoid. Snake 1989; 21: 6-8.
24. Kawamura Y, Sawai Y. Study on the Immunogenicity of Purified Toxoid of Siamese Cobra (Naja Naja kaouthia) Venom. Snake 1989; 21: 81-4.
25. Fujimaki H, Ozawa M, Imai T, Kubota K, Watanabe N. Adjuvant Effects of Aluminium Silicate on IgE and IgG1 Antibody Production in Mice. Int. Archs Allergy Appl. Immun. 1984; 75: 351-6.
26. 3. II. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 1923; 56: 1117-21.
27. Willstätter R, Kraut H. Über die Hydroxide und ihre Hydrate in den verschiedenen Tonerde-Gelen. V. Mitteilung über Hydrate und Hydrogele. Ber. Dtsch. Chem. Ges. 1924; 57: 1082-91.
28. Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminium Compounds Used as Adjuvants in Vaccines. Pharm. Res. 1990; 7: 1282-8.
29. Johnston CF, Wang S-L, Hem SL. Measuring the surface area of aluminium hydroxide adjuvant. J. Pharm. Sci. 2002; 91: 1702-6.
30. Relyveld EH, Raynaud M. Methods of Toxin and Antitoxin Assays in vitro. In: Williams CA, Chase MW (eds). Methods in Immunology and Immunochemistry, Vol. IV. New York: Academic Press, 1977; 283-93.
31. Weeke B, Weeke E, Løwenstein H. The Adsorption of Serum Proteins to Aluminium Hydroxide Gel Examined by Means of Quantitative Immunoelectrophoresis. In: Axelsen NH (eds). Quantitative Immunoelectrophoresis. New developments and applications. Oslo: Universitetsforlaget, 1975; 149-54.
32. Lindblad EB. Aluminium Adjuvants. In: Stewart-Tull DES (ed.). The Theory and Practical Application of Adjuvants. New York: John Wiley & Sons, 1995; 21-35.
33. Smith PK, Krohn RI, Hermanson GT et al. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985; 150: 76-85.
34. Thiele GM, Rogers J, Collins M, Yasuda N, Smith D, McDonald TL. An Enzyme-Linked Immunosorbent Assay for the Detection of Antitetanus Toxoid Antibody Using Aluminium-Adsorbed Coating Antigen. J. Clin. Lab. Anal. 1990; 4: 126-9.
35. Katz JB, Hanson SK, Patterson PA, Stoll IR. In vitro assessment of viral antigen content in inactivated aluminium hydroxide adjuvanted vaccines. J. Virol. Meth. 1989; 25: 101-8.
36. May JC, Progar JJ, Chin R. The aluminium content of biological products containing aluminium adjuvants: determination by atomic absorption spectrometry. J. Biol. Stand. 1984; 12: 175-83.
37. Flebbe LM, Braley-Mullen H. Immunopotentiating effects of the adjuvants SGP and Quil-A. I. Antibody responses to T-dependent and T-independent antigens. Cell. Immunol. 1986; 99: 119-27.
38. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant Properties of Aluminum and Calcium Compounds. In: Powell MF, Newman MJ (eds). Vaccine Design: The Subunit, Adjuvant Approach. New York: Plenum Press, 1995; 229-48.
39. Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: Effect on antigen uptake and antigen presentation. Clin. Exp. Immunol. 1985; 61: 143-51.
40. Seeber SJ, White JL, Hem SL. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991; 9: 201-3.
41. Iyer S, Robinett RSR, HogenEsch H, Hem SL. Mechanism of adsorption of hepatitis B surface antigen by aluminium hydroxide adjuvant. Vaccine 2004; 22: 1475-9.
42. Iyer S, HogenEsch H, Hem SL. Effect of the degree of phosphate substitution in aluminium hydroxide adjuvant on the adsorption of phosphorylated proteins. Pharm. Dev. Tech. 2003; 8: 81-6.
43. Hem SL, White JL. Characterization of Aluminium Hydroxide for Use as an Adjuvant in Parenteral Vaccines. J. Parent. Sci. Tech. 1984; 38: 2-11.
44. Al-Shakhshir RH, Regnier FE, White JL, Hem SL. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995; 13: 41-4.
45. Rinella JV, White JL, Hem SL. Effect of anions on model aluminium-adjuvant-containing vaccines. J. Colloid Interface Sci. 1995; 172: 121-30.
46. Rinella JV, White JL, Hem SL. Effect of pH on the elution of model antigens from aluminium-containing adjuvants. J. Colloid Interface Sci. 1998; 205: 161-5.
47. Rinella JV, Workman RF, Hermodson MA, White JL, Hem SL. Elutability of proteins from aluminium-containing vaccine adjuvants by treatment with surfactants. J. Colloid Interface Sci. 1998; 197: 48-56.
48. Bomford R. The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, Alhydrogel, Corynebacterium parvum, Bordetella pertussis, muramyl dipeptide and saponin. Clin. Exp. Immunol. 1980; 39: 435-41.
49. Dillon SB, Demuth SG, Schneider MA et al. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant. Vaccine 1992; 10: 309-18.
50. Walls RS. Eosinophil Response to Alum Adjuvants. Involvement of T Cells in Non-Antigen-Dependent Mechanisms. Proc. Soc. Exp. Biol. Med. 1977; 156: 431-5.
51. Grun JL, Maurer PH. Different T Helper Cell Subsets Elicited in Mice Utilizing Two Different Adjuvant Vehicles. The Role of Endogenous Interleukin-1 in Proliferative Responses. Cell. Immunol. 1989; 121: 134-45.
52. Sagara T, Mori S, Ohkawara S, Goto F, Takagi K, Yoshinaga M. A limited role of IL-1 in immune-enhancement by adjuvants. Immunol. 1990; 71: 251-7.
53. Lindblad EB, Elhay MJ, Suva R, Appelberg R, Andersen P. Adjuvant modulation of immune responses to tuberculosis subunit vaccines. Infect. Immun. 1997; 65: 623-9.
54. Jankovic D, Caspar P, Zweig M et al. Adsorption to aluminium hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp 120. J. Immunol. 1999; 163: 4481-8.
55. Pollock KGJ, Conacher M, Wei X-Q, Alexander J, Brewer JM. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper I response induced by alum-absorbed interleukin-12. Immunology 2003; 108: 137-43.
56. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur. J. Immunol. 1996; 26: 2062-6.
57. Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J. Immunol. Meth. 1989; 121: 157-66.
58. Hamaoka T, Katz DH, Bloch KJ, Benacerraf B. Hapten-Specific IgE Antibody Responses in Mice. I. Secondary IgE Response in Irradiated Recipients of Syngeneic Primed Spleen Cells. J. Exp. Med. 1973; 138: 306-11.
59. Knopf PM, Goldberg M, Grossi CA, Cappello M, Coulter ST. Induction of Resistance to Schistosoma mansoni by Immunization with Subfractions of Worms. Am. J. Trop. Med. Hyg. 1988; 38: 515-28.
60. Horowitz S, Smolarsky M, Arnon R. Protection against Schistosoma mansoni achieved by immunization with sonicated parasite. Eur. J. Immunol. 1982; 12: 327-32.
61. Uede T, Huff TF, Ishizaka K. Formation of IgE Binding Factors by Rat T Lymphocytes. V. Effect of Adjuvant for the Priming Immunization on the Nature of IgE Binding Factors Formed by Antigenic Stimulation. J. Immunol. 1982; 129: 1384-90.
62. Uede T, Ishizaka K. Formation of IgE Binding Factors by Rat T Lymphocytes. VI. Cellular Mechanisms for the Formation of IgE-Potentiating Factor and IgE-Suppressive Factor by Antigenic Stimulation of Antigen Primed Spleen Cells. J. Immunol. 1982; 129: 1391-7.
63. European Pharmacopeia. Vaccines for Human Use, 3rd edn. 1997; 1697.
64. Code of Federal Regulations 21, vol. 7: Sec. 610.15 (Constituent Materials). Revised 1 April 2003. US Government Publication.
65. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002; 20: 709-60.
66. 4 on Purified Influenza Virus Hemagglutinins in Man. J. Immunol. 1968; 100: 1139-40.
67. Cvjetanovic B, Uemura K. The Present Status of Field and Laboratory Studies of Typhoid and Paratyphoid Vaccines. Bull. WHO 1965; 32: 29-36.
68. Francis MJ, Fry CM, Rowlands DJ et al. Immune response to uncoupled peptides of foot-and-mouth disease virus. Immunology 1987; 61: 1-6.
69. Francis MJ, Fry CM, Rowlands DJ et al. Immunological Priming with Synthetic Peptides of Foot-and-Mouth Disease Virus. J. General Vir. 1985; 66: 2347-54.
70. Lew AM, Anders RF, Edwards SJ, Langford CJ. Comparison of Antibody Avidity and Titre Elicited by Peptide as a Protein Conjugate or as Expressed in Vaccinia. Immunology 1988; 65: 311-14.
71. Geerligs HJ, Weijer WJ, Welling GW, Welling-Wester S. The Influence of Different Adjuvants on the Immune Response to a Synthetic Peptide Comprising Amino Acid Residues 9-21 of Herpes Simplex Virus Type 1. J. Immunol Meth. 1989; 124: 95-102.
72. Ulmer JB, DeWitt CM, Chastain M et al. Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine 2000; 18: 18-28.
73. Kwissa M, Lindblad EB, Schirmbeck R, Reimann J. Co-delivery of a DNA vaccine and a protein vaccine with aluminium phosphate stimulates a potent and multivalent immune response. J. Mol. Med. 2003; 81: 502-10.
74. Martyn CN, Barker DJP, Osmond C, Harris EC, Edwardson JA, Lacey RF. Geographical relation between Alzheimers disease and aluminium in drinking water. Lancet 1989; 1: 59-62.
75. 26Al. Vaccine 1997; 15: 1314-18.
76. Goldenthal KL, Cavagnaro JA, Alving C, Vogel FR. Safety Evaluation of Vaccine Adjuvants. NCVDG Working Groups. AIDS Res. Human Retroviruses 1993; 9 (Suppl. 1): s47-s51.
77. Böhler-Sommeregger K, Lindemayr H. Contact sensitivity to aluminium. Contact Dermatitis 1986; 15: 278-81.
78. Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine 1993; 11: 293-306.
79. Frost L, Johansen P, Pedersen S, Veien N, Ostergaard P, Nielsen M. Persistent Subcutaneous Nodules in Children Hyposensitized with Aluminium-Containing Allergen Extracts. Allergy 1985; 40: 368-72.
80. Collier LH, Polakoff S, Mortimer J. Reactions and Antibody Responses to Reinforcing Doses of Adsorbed and Plain Tetanus Vaccines. Lancet 1979; 1(8131): 1364-7.
81. Matzinger P. Tolerance, danger and the extended family. Ann. Rev. Immunol. 1994; 12: 991-1045.
82. Aprile MA, Wardlaw AC. Aluminium Coumpounds as Adjuvants for Vaccines and Toxoids in Man: a Review. Can. J. Public Health 1966; 57: 343-54.
83. Butler NR, Voyce MA, Burland WL, Hilton ML. Advantages of Aluminium Hydroxide Adsorbed Combined Diphtheria, Tetanus, and Pertussis Vaccines for the Immunization of Infants. Br. Med. J. 1969; 1: 663-6.
84. Shi Y, HogenEsch H, Regnier FE, Hem SL. Detoxification of endotoxin by aluminium hydroxide adjuvant. Vaccine 2001; 19: 1747-52.
85. Norimatsu M, Ogikubo Y, Aoki A et al. Effects of aluminium adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine 1995; 13: 1325-9.
86. Chaby R, Caroff M. Lipopolysaccharides of Bordetella pertussis Endotoxin. In: Wardlaw AC, Parton P (eds). Pathogenesis and Immunity in Pertussis. New York: John Wiley and Sons, 1988; 247-71.
87. Sun H, Pollock KGJ, Brewer JM. Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 2003; 21: 849-55.
88. Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991; 9: 408-15.